Skip to content

Prospective Follow-up of Patients With Glycogen Storage Disease Type III

Prospective Follow-up of Patients With Glycogen Storage Disease Type III

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01563705
Acronym
PRO GSDIII
Enrollment
30
Registered
2012-03-27
Start date
2011-02-28
Completion date
2016-08-31
Last updated
2012-12-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuromuscular Disorders

Keywords

Neuromuscular Disorders, GSD III, glycogen storage disease

Brief summary

The aim of this study is to improve knowledge of natural history and methods of monitoring the evolution of Glycogen storage disease type III regarding the muscle and to study the prospective approach of large series of patients, and using the same protocol for the follow up of the children and adults.

Interventions

PROCEDUREDifferent motor function tests

Time to rise from a chair, time to go from lying to sitting, time to go from lying to standing, time to cover 10 meters, time to climb 4 steps

PROCEDUREManual dexterity assessment

Purdue pegboard test

Sponsors

Institut de Myologie, France
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
10 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients with a debranching enzyme deficiency confirmed by enzymatic analysis (debranching enzyme deficiency). * Written consent * Age: at least 10 years * Affiliated with a social security system

Exclusion criteria

* Pregnant and lactating women

Design outcomes

Primary

MeasureTime frame
Knee flexion and extension strengthat baseline
Time to perform each motor function testat baseline
Gait speed measured during the 6 minutes walk testat baseline

Secondary

MeasureTime frame
Accelerometric variables measured for the 6 minutes walk testAt baseline
NMR variables measured during each specific NMR sequenceat baseline

Countries

France

Contacts

Primary ContactPascal Laforet, MD
pascal.laforet@psl.aphp.fr00 331 42 16 37 75
Backup ContactPierre Carlier, MD, PhD
p.carlier@institut-myologie.org

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026